Kiniksa Pharmaceuticals (KNSA) Competitors $20.02 +0.33 (+1.68%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$20.00 -0.02 (-0.07%) As of 02/21/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KNSA vs. ELAN, LNTH, NUVL, CYTK, VRNA, GRFS, TGTX, KRYS, SWTX, and BHVNShould you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Elanco Animal Health (ELAN), Lantheus (LNTH), Nuvalent (NUVL), Cytokinetics (CYTK), Verona Pharma (VRNA), Grifols (GRFS), TG Therapeutics (TGTX), Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals vs. Elanco Animal Health Lantheus Nuvalent Cytokinetics Verona Pharma Grifols TG Therapeutics Krystal Biotech SpringWorks Therapeutics Biohaven Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability. Does the MarketBeat Community believe in KNSA or ELAN? Kiniksa Pharmaceuticals received 32 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 65.02% of users gave Kiniksa Pharmaceuticals an outperform vote while only 54.51% of users gave Elanco Animal Health an outperform vote. CompanyUnderperformOutperformKiniksa PharmaceuticalsOutperform Votes17165.02% Underperform Votes9234.98% Elanco Animal HealthOutperform Votes13954.51% Underperform Votes11645.49% Is KNSA or ELAN more profitable? Elanco Animal Health has a net margin of 4.60% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Elanco Animal Health's return on equity of 6.78% beat Kiniksa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals-2.36% -7.31% -5.95% Elanco Animal Health 4.60%6.78%3.03% Do analysts recommend KNSA or ELAN? Kiniksa Pharmaceuticals currently has a consensus target price of $36.60, indicating a potential upside of 82.82%. Elanco Animal Health has a consensus target price of $16.00, indicating a potential upside of 45.24%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Elanco Animal Health 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media prefer KNSA or ELAN? In the previous week, Elanco Animal Health had 8 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 10 mentions for Elanco Animal Health and 2 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 0.56 beat Elanco Animal Health's score of 0.18 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Which has higher earnings and valuation, KNSA or ELAN? Kiniksa Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals$384.10M3.76$14.08M-$0.14-143.00Elanco Animal Health$4.42B1.23-$1.23B$0.4027.54 Do institutionals & insiders hold more shares of KNSA or ELAN? 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Comparatively, 0.6% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, KNSA or ELAN? Kiniksa Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. SummaryKiniksa Pharmaceuticals and Elanco Animal Health tied by winning 9 of the 18 factors compared between the two stocks. Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.45B$7.04B$5.77B$8.95BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-142.996.1326.4618.81Price / Sales3.76314.26449.1576.64Price / CashN/A67.8344.0437.47Price / Book3.216.747.634.64Net Income$14.08M$138.11M$3.18B$245.69M7 Day Performance1.42%-2.02%-1.82%-2.63%1 Month Performance7.00%-1.54%0.22%-2.37%1 Year Performance0.30%-3.14%17.49%13.65% Kiniksa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals3.1746 of 5 stars$20.02+1.7%$36.60+82.8%+0.3%$1.45B$384.10M-142.99220Upcoming EarningsELANElanco Animal Health4.0515 of 5 stars$11.26-3.4%$16.29+44.7%-31.9%$5.57B$4.42B28.159,300Analyst ForecastLNTHLantheus4.5798 of 5 stars$79.94-2.5%$131.86+64.9%+37.9%$5.56B$1.30B13.30700Analyst RevisionNews CoveragePositive NewsNUVLNuvalent2.1211 of 5 stars$77.93-3.7%$112.36+44.2%-3.7%$5.54BN/A-22.4640Upcoming EarningsInsider TradeCYTKCytokinetics4.1875 of 5 stars$46.16+10.9%$82.00+77.6%-34.3%$5.45B$7.53M-8.58250High Trading VolumeVRNAVerona Pharma1.9349 of 5 stars$64.21+4.1%$57.14-11.0%+309.6%$5.13B$460,000.00-33.4430GRFSGrifols1.9016 of 5 stars$7.32-2.0%N/A-14.9%$5.03B$7.13B6.2023,737Upcoming EarningsTGTXTG Therapeutics4.4797 of 5 stars$30.71-0.1%$40.67+32.4%+137.2%$4.78B$233.66M-307.07290Positive NewsKRYSKrystal Biotech4.4745 of 5 stars$153.24-1.6%$206.67+34.9%+73.9%$4.41B$50.70M86.58210Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSWTXSpringWorks Therapeutics1.25 of 5 stars$57.43-2.0%$70.83+23.3%+18.4%$4.27B$5.45M-14.80230Earnings ReportAnalyst ForecastInsider TradeNews CoverageBHVNBiohaven3.4075 of 5 stars$41.45-0.8%$63.15+52.4%-20.8%$4.19BN/A-4.43239Short Interest ↓Positive News Related Companies and Tools Related Companies Elanco Animal Health Alternatives Lantheus Alternatives Nuvalent Alternatives Cytokinetics Alternatives Verona Pharma Alternatives Grifols Alternatives TG Therapeutics Alternatives Krystal Biotech Alternatives SpringWorks Therapeutics Alternatives Biohaven Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KNSA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
